医学临床研究
   Apr. 6, 2025    Home  |  About Journal  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages Board  |  Contact Us  |  中文
JOURNAL OF CLINICAL RESEARCH  2021, Vol. 38 Issue (4): 484-487    DOI: 10.3969/j.issn.1671-7171.2021.04.002
Current Issue | Archive | Adv Search |
Effects of Aldibenzoquinone Combined with Nierergerine on Oxidative Stress in Patients with Chronic Cerebral Ischemia Dizziness
LI Jing, ZHANG Ni
The Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an Shaanxi 710002
Download: PDF (1162 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  【Objective】 To investigate the effect of aldibenzoquinone combined with Nimergoline on oxidative stress in patients with chronic cerebral ischemia dizziness. 【Methods】 A total of 128 patients with chronic cerebral ischemia dizziness were randomly divided into two groups. The control group was treated with aldibenzoquinone, while the observation group was treated with aldibenzoquinone combined with nimergoline. The levels of inflammatory cytokines (TNF-α, IL-6 and IL-23), never cytokine (BDNF and NGF) in serum and oxidative stress factors (NO, SOD and MDA) before and after treatment were compared between the two groups. 【Results】 There were no significant differences in all factors between the two groups before treatment (P>0.05). After treatment, the clinical efficacy of the observation group was significantly better than that of the control group (P<0.05). The levels of TNF-α, IL-6 and IL-23 inflammatory factors in the observation group were lower than those in the control group (P<0.05). The clinical treatment effect of the observation group was significantly better than that of the control group (P<0.05). The levels of nerve cytokines such as BDNF and NGF in the observation group after treatment were significantly higher than those in the control group (P<0.05). The levels of NO and MDA in the observation group were lower than those in the control group, while the level of SOD was higher than that in the control group (P<0.05). 【Conclusion】 The treatment of chronic cerebral ischemia dizziness patients with aldibenzoquinone combined with nimergoline can improve the level of oxidative stress factor, improve the clinical treatment effect, reduce the level of inflammatory factor and improve the content of nerve cytokines. The clinical effect is satisfactory and it is worthy of application.
Key wordsIschemic Attack, Transient/DT      Ergolines/TU      Ubiquinone/TU      Oxidative Stress     
Received: 04 April 2019     
PACS:  R743.31  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
LI Jing
ZHANG Ni
Cite this article:   
LI Jing,ZHANG Ni. Effects of Aldibenzoquinone Combined with Nierergerine on Oxidative Stress in Patients with Chronic Cerebral Ischemia Dizziness[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(4): 484-487.
URL:  
http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2021.04.002     OR     http://journal07.magtech.org.cn/yxlcyj/EN/Y2021/V38/I4/484
Copyright © Editorial Board of JOURNAL OF CLINICAL RESEARCH
Supported by:Beijing Magtech